U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07319195) titled 'Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)' on Nov. 26, 2025.
Brief Summary: The goal of this clinical trial is to study the safety, feasibility, histologic and immunological effects of Mitazalimab, a CD40 agonistic antibody, when administered either alone or in combination with PD-1 inhibition prior to surgical resection.
The investigator hypothesizes that preoperative administration of CD40 agonist with or without PD-1 inhibitor intratumorally will demonstrate an acceptable safety profile, will not result in an unplanned delay in surgery, and will lead to increased immune activation.
Subjects will receiv...